ENTHEOS LABS

What this means for you

Not registered yet, but its 27 May 2026 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.

Record

Serial number

99847643

Mark type

Word mark

Filed

27 May 2026

Attorney of record

Brian J. Focarino

Goods and services

• Class 042 — Scientific and technological services: Research and development services in the fields of pharmaceuticals, neuroplastogens, psychedelic medicines, natural products, botanically derived therapeutic agents, plant-derived molecules, and therapeutics for inflammatory diseases and disorders and diseases and disorders of the central and peripheral nervous system, including pain, psychiatric disorders and neurological disorders in humans; Drug discovery services; pharmaceutical discovery services; biological, chemical, pharmacological, metabolomic, genomic, transcriptomic, proteomic, electrophysiological, and neuroimaging research services for identifying, characterizing, optimizing, and developing therapeutic compounds; Scientific research services, namely, cultivation, extraction, isolation, purification, fractionation, sub-fractionation, identification, characterization, metabolite profiling, and bioactivity-guided screening of botanicals, plants, fungi, plant extracts, fungal extracts, natural products, and biologically active compounds for pharmaceutical research and development purposes; Research and development services relating to novel molecules from botanicals, namely, discovery and development of novel chemotypes, derivatives, analogs, salts, polymorphs, crystal forms, deuterated derivatives, formulations, metabolites, biologically active combinations, and compositions of matter for therapeutic use; Development and optimization of proprietary extraction, fractionation, isolation, purification, bioengineering, biosynthesis, fermentation, cultivation, and manufacturing processes for producing pharmaceutical compounds, natural products, botanically derived active agents, and neuroplastogens; Scientific research and development services relating to engineered cells, engineered plant cells, cell cultures, plant cell lines, transformed plant tissue, and engineered plants for biosynthesis, expression, production, screening, and characterization of therapeutic agents, natural products, and neuroplastogens; Providing temporary use of non-downloadable software, databases, artificial intelligence models, and machine learning models for phytochemical fingerprinting, metabolomics analysis, compound prediction, structure-activity analysis, receptor binding prediction, bioassay prioritization, neuroplasticity assay analysis, high-content imaging analysis, electrophysiology analysis, and pharmaceutical candidate selection; Artificial intelligence and machine learning enabled pharmaceutical research services, namely, predicting which plant fractions, extraction methods, compounds, compound pairs, and assays are most likely to yield neuroplasticity-enhancing or therapeutically active drug candidates; In vitro, ex vivo, and cell-based screening services for others in the fields of neuroplasticity, neuronal morphology, neuronal connectivity, network electrophysiology, receptor pharmacology, biomarker discovery, and central and peripheral nervous system drug discovery; Pharmaceutical formulation development services, including development of orally disintegrating, sublingual, buccal, transmucosal, rapid-disintegrating, and rapid-dissolving dosage forms; pharmaceutical product evaluation and testing of pharmacokinetic, pharmacodynamic, stability, bioavailability, tolerability, and manufacturing characteristics; Scientific and medical research services relating to clinical biomarkers, patient selection, dose selection, dosing intervals, route of administration, methods of treatment, and clinical trial design for pharmaceuticals, neuroplastogens, and therapies for psychiatric, neurological, pain, inflammatory, and central or peripheral nervous system disorders

Owner

• Entheos Labs, Inc., Brookline, MA, US

Prosecution history

• 02 Oct 2026 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
• 02 Oct 2026 — NON-FINAL ACTION E-MAILED
• 02 Oct 2026 — NON-FINAL ACTION WRITTEN
• 25 Sept 2026 — ASSIGNED TO EXAMINER
• 24 Sept 2026 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
• 27 May 2026 — APPLICATION FILING RECEIPT MAILED
• 27 May 2026 — NEW APPLICATION ENTERED